Xspray Pharma Reports Positive P-I Trial Results of HyNap-Dasa for the Treatment of Chronic Myeloid Leukemia (CML)
Shots:
- The P-I BE study involves assessing of PK limitations i.e. Cmax- AUC for Xspray’s leading product HyNap-Dasa formulated vs Sprycel (Dasatinib)
- The P-I study (N=16) with healthy candidates administrating single dose of each product- demonstrated positive results while confirming the validity of Xspray's patented formulation technology
- The results will be helpful in designing of planned registration study for ANDA application of HyNap-Dasa
Ref: PRNewswire | Image: Xspray Pharma
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com